Ranveer Singh has been in the news in recent weeks following the consequences of his reported exit from Excel Entertainment’s upcoming ambitious project Don 3. A number of people from the ...
The prevalence of overweight and obesity represents a global public health challenge 1. Incretin mimetic therapies, including glucagon-like peptide 1 (GLP-1) receptor agonists and dual ...
News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The eight-acre project would ...
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, ...
Getting your Trinity Audio player ready... In late September 2025, as the Trump administration’s aggressive immigration enforcement action known as Operation Midway Blitz was in high gear, protests ...
Reports of deaths come as Egypt hosts new truce talks Netanyahu told Israeli forces to expand Gaza control Most of Gazans now live in tiny sliver of land CAIRO, June 8 (Reuters) - Israeli strikes ...
Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and ...
News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results